2000
Outcome of Children in the Indomethacin Intraventricular Hemorrhage Prevention Trial
Ment L, Vohr B, Allan W, Westerveld M, Sparrow S, Schneider K, Katz K, Duncan C, Makuch R. Outcome of Children in the Indomethacin Intraventricular Hemorrhage Prevention Trial. Pediatrics 2000, 105: 485-491. PMID: 10699097, DOI: 10.1542/peds.105.3.485.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Inflammatory Agents, Non-SteroidalBrain Damage, ChronicCerebral HemorrhageCerebral VentriclesChild, PreschoolDose-Response Relationship, DrugFemaleFollow-Up StudiesHumansIndomethacinInfantInfant, NewbornInfant, Premature, DiseasesMaleNeurologic ExaminationNeuropsychological TestsPregnancyConceptsLow-dose indomethacinIntraventricular hemorrhagePlacebo childrenIndomethacin therapyPreterm infantsEarly administrationNeurologic examinationPrevention trialsLow birth weight preterm infantsStudy childrenBirth weight preterm infantsSeverity of IVHLow birth weight survivorsMean gestational ageWeight preterm infantsAdverse neurodevelopmental outcomesOutcome of childrenStandard neurologic examinationYears of ageNeurodevelopmental handicapPreterm neonatesNeurodevelopmental examinationNeurodevelopmental outcomesCerebral palsyGestational age
1990
A multicenter clinical trial of oral ribavirin in HIV-infected patients with lymphadenopathy. The Ribavirin-LAS Collaborative Group.
Roberts R, Dickinson G, Heseltine P, Leedom J, Mansell P, Rodriguez S, Johnson K, Lubina J, Makuch R. A multicenter clinical trial of oral ribavirin in HIV-infected patients with lymphadenopathy. The Ribavirin-LAS Collaborative Group. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1990, 3: 884-92. PMID: 1974628.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdministration, OralAdolescentAdultCD4 AntigensCD4-Positive T-LymphocytesDose-Response Relationship, DrugDouble-Blind MethodEvaluation Studies as TopicHumansImmunoblastic LymphadenopathyLeukocyte CountMaleMiddle AgedMulticenter Studies as TopicRandomized Controlled Trials as TopicRibavirinRibonucleosidesConceptsOral ribavirinActive treatmentBaseline CD4 cell countMajor protocol violationsCD4 cell countPlacebo-controlled trialMulticenter clinical trialSignificant differencesPlacebo patientsPlacebo groupPlacebo treatmentStudy entryTreat analysisWashout periodDaily dosesClinical trialsKaposi's sarcomaProtocol violationsMedical CenterTreatment superiorityTreatment groupsPlaceboRibavirinPatientsOverall significant difference
1986
Late intensive combined modality therapy followed by autologous bone marrow infusion in extensive-stage small-cell lung cancer.
Ihde D, Deisseroth A, Lichter A, Bunn P, Carney D, Cohen M, Veach S, Makuch R, Johnston-Early A, Abrams R. Late intensive combined modality therapy followed by autologous bone marrow infusion in extensive-stage small-cell lung cancer. Journal Of Clinical Oncology 1986, 4: 1443-54. PMID: 3020181, DOI: 10.1200/jco.1986.4.10.1443.Peer-Reviewed Original ResearchConceptsExtensive-stage SCLC patientsProphylactic cranial irradiationComplete responseAutologous bone marrowPartial responseSCLC patientsModality therapyTumor regressionMedical conditionsExtensive-stage small-cell lung cancer patientsExtensive-stage small-cell lung cancerSmall cell lung cancer patientsAutologous bone marrow infusionMajor non-hematologic toxicitySmall cell lung cancerExtensive-stage patientsNon-hematologic toxicitiesWeeks of cyclophosphamideWeeks of vincristineBone marrow infusionGood medical conditionPoor medical conditionLung cancer patientsBetter tumor regressionCranial irradiation
1982
Dose-response curves for predicting misonidazole-induced peripheral neuropathy.
Schwade J, Makuch R, Strong J, Glatstein E. Dose-response curves for predicting misonidazole-induced peripheral neuropathy. Journal Of The National Cancer Institute 1982, 66: 1743-50. PMID: 6288238.Peer-Reviewed Original ResearchConceptsPeripheral neuropathyLinear logistic regression analysisTotal cumulative doseLogistic regression analysisLogistic regression modelsDose-response curveCumulative AUCCumulative dosePlasma eliminationPlasma concentrationsNeuropathyLinear logistic regression modelPharmacokinetic parametersPharmacokinetic curveCancer treatmentToxic agentsRegression analysisAUCRegression modelsPatientsPharmacokineticsDoseMisonidazole